Perceptive Advisors Sells 1 Million Arcellx Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ACLX?
Source: Fool
- Share Reduction Details: Perceptive Advisors disclosed a sale of 1,002,282 shares of Arcellx in an SEC filing dated February 17, 2026, with an estimated transaction value of $79.96 million, indicating growing concerns about the company's future prospects.
- Value Decline: The quarter-end value of Arcellx's holdings decreased by $107.06 million, a figure that reflects both the reduction in shares and price fluctuations, highlighting a waning investor confidence in its market performance.
- Market Performance Analysis: As of February 17, 2026, Arcellx shares were priced at $70.20, up 9.2% over the past year but underperforming the S&P 500 by 4.3 percentage points, suggesting increasing competitive pressure in the biotechnology sector.
- Clinical Progress and Risks: Arcellx's anti-cel is currently in Phase 3 trials for relapsed or refractory multiple myeloma, and while its partnership with Gilead strengthens its market position, recent stock volatility raises concerns about the sustainability of its long-term prospects, necessitating investor attention on the durability of its scientific advancements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACLX
Wall Street analysts forecast ACLX stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 66.530
Low
100.00
Averages
113.14
High
130.00
Current: 66.530
Low
100.00
Averages
113.14
High
130.00
About ACLX
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perceptive Advisors Sells 1 Million Arcellx Shares
- Share Reduction Details: Perceptive Advisors disclosed a sale of 1,002,282 shares of Arcellx in an SEC filing dated February 17, 2026, with an estimated transaction value of $79.96 million, indicating growing concerns about the company's future prospects.
- Value Decline: The quarter-end value of Arcellx's holdings decreased by $107.06 million, a figure that reflects both the reduction in shares and price fluctuations, highlighting a waning investor confidence in its market performance.
- Market Performance Analysis: As of February 17, 2026, Arcellx shares were priced at $70.20, up 9.2% over the past year but underperforming the S&P 500 by 4.3 percentage points, suggesting increasing competitive pressure in the biotechnology sector.
- Clinical Progress and Risks: Arcellx's anti-cel is currently in Phase 3 trials for relapsed or refractory multiple myeloma, and while its partnership with Gilead strengthens its market position, recent stock volatility raises concerns about the sustainability of its long-term prospects, necessitating investor attention on the durability of its scientific advancements.
See More
First Turn Management Exits Entire Stake in Arcellx
- Stake Reduction: On February 13, 2026, First Turn Management disclosed in an SEC filing that it sold its entire stake of 313,733 shares in Arcellx for approximately $25.76 million, indicating a potential reduction in confidence towards the company.
- Market Performance: As of February 13, 2026, Arcellx shares were priced at $68.50, reflecting a 7.5% increase over the past year, yet underperforming the S&P 500 by 4.3 percentage points, highlighting its relative weakness in the high-risk biotech sector.
- Portfolio Reallocation: The sale suggests that First Turn Management is rotating capital towards more promising biotech firms like Abivax and Revolution Medicines, which may indicate a lack of confidence in Arcellx's growth prospects moving forward.
- Industry Context: Arcellx focuses on developing cell-based immunotherapies for cancer, and despite a diversified pipeline, investors in clinical-stage biotech typically prioritize companies with clear competitive advantages and timelines, which may not currently favor Arcellx.
See More
Arcellx's Novel D-Domain Binder Accepted for Presentation at 2026 Tandem Meetings
- Preclinical Study Results: Arcellx's D-Domain binder showed no tonic signaling or off-target activity in preclinical assessments, supporting its unique target-specific binding profile and potentially positioning anito-cel as a best-in-class safety option, enhancing its competitiveness in multiple myeloma treatment.
- Dual VHH Binder Risks: Specific off-target activity against Claudin-9 was observed with the dual VHH binder compared to cilta-cel, indicating a potential increase in off-tumor toxicities, thereby highlighting the safety advantages of the D-Domain binder.
- Cell Activation and Cytokine Release: CAR T cell activation and cytokine release were observed with dual VHH and scFv binders in the absence of BCMA antigen, while the D-Domain did not exhibit tonic signaling, further validating its safety and specificity.
- Conference Presentation Details: The findings will be presented on February 5, 2026, at the Tandem Meetings in Salt Lake City, showcasing the D-Domain binder's potential for anti-tumor activity while minimizing tonic signaling and off-target reactivity risks.
See More
Director David Lubner Sells 6,000 Shares of Arcellx Stock
- Transaction Overview: On January 20, 2026, Director David Charles Lubner executed the sale of 6,000 shares of Arcellx common stock for approximately $450,000, indicating a significant reduction in his ownership stake.
- Ownership Stake Reduction: This transaction reduced Lubner's direct holdings by 21.69%, from 27,659 shares to 21,659 shares, while his 59,405 options remained unchanged, suggesting a potential shift in confidence regarding the company's future.
- Market Performance Insight: As of January 20, 2026, Arcellx's stock price stood at $68.31 with a market capitalization of $3.95 billion; despite a 15% decline in stock value in 2025, the company has sufficient funding to operate through 2028, indicating some financial stability.
- Clinical Development and Investor Outlook: Arcellx has made significant progress with its multiple myeloma treatment, advancing to phase two development, which could become a major revenue driver if successful, although the company still faces challenges with negative operating income.
See More
FDA Draft Guidance Boosts Arcellx (ACLX) and Legend Biotech (LEGN) Stock Prices
- FDA Guidance Impact: The U.S. FDA's draft guidance allows minimal residual disease and complete response as endpoints for accelerated approval in multiple myeloma treatments, leading to a stock price increase for Arcellx (ACLX) and Legend Biotech (LEGN), reflecting market optimism for new therapies.
- Collaborative Prospects: Legend Biotech's partnership with Johnson & Johnson (JNJ) on the Carvykti cell therapy has already incorporated MRD negativity as an endpoint in the CARTITUDE-6 trial, which analysts view as a positive development for its market performance.
- Market Competition Analysis: Analysts highlight that Arcellx's anito-cel therapy is also expected to enter the market based on MRD negativity, enhancing its competitiveness in the second to fourth-line treatment settings and increasing investment appeal in this sector.
- Investment Rating Changes: Jefferies maintains an Outperform rating on Legend Biotech with a target price of $66, noting that while the stock trades at a significant discount, the FDA guidance provides a clear positive signal for its future growth.
See More
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
See More
Perceptive Advisors Sells 1 Million Arcellx Shares
- Share Reduction Details: Perceptive Advisors disclosed a sale of 1,002,282 shares of Arcellx in an SEC filing dated February 17, 2026, with an estimated transaction value of $79.96 million, indicating growing concerns about the company's future prospects.
- Value Decline: The quarter-end value of Arcellx's holdings decreased by $107.06 million, a figure that reflects both the reduction in shares and price fluctuations, highlighting a waning investor confidence in its market performance.
- Market Performance Analysis: As of February 17, 2026, Arcellx shares were priced at $70.20, up 9.2% over the past year but underperforming the S&P 500 by 4.3 percentage points, suggesting increasing competitive pressure in the biotechnology sector.
- Clinical Progress and Risks: Arcellx's anti-cel is currently in Phase 3 trials for relapsed or refractory multiple myeloma, and while its partnership with Gilead strengthens its market position, recent stock volatility raises concerns about the sustainability of its long-term prospects, necessitating investor attention on the durability of its scientific advancements.
See More
First Turn Management Exits Entire Stake in Arcellx
- Stake Reduction: On February 13, 2026, First Turn Management disclosed in an SEC filing that it sold its entire stake of 313,733 shares in Arcellx for approximately $25.76 million, indicating a potential reduction in confidence towards the company.
- Market Performance: As of February 13, 2026, Arcellx shares were priced at $68.50, reflecting a 7.5% increase over the past year, yet underperforming the S&P 500 by 4.3 percentage points, highlighting its relative weakness in the high-risk biotech sector.
- Portfolio Reallocation: The sale suggests that First Turn Management is rotating capital towards more promising biotech firms like Abivax and Revolution Medicines, which may indicate a lack of confidence in Arcellx's growth prospects moving forward.
- Industry Context: Arcellx focuses on developing cell-based immunotherapies for cancer, and despite a diversified pipeline, investors in clinical-stage biotech typically prioritize companies with clear competitive advantages and timelines, which may not currently favor Arcellx.
See More
Arcellx's Novel D-Domain Binder Accepted for Presentation at 2026 Tandem Meetings
- Preclinical Study Results: Arcellx's D-Domain binder showed no tonic signaling or off-target activity in preclinical assessments, supporting its unique target-specific binding profile and potentially positioning anito-cel as a best-in-class safety option, enhancing its competitiveness in multiple myeloma treatment.
- Dual VHH Binder Risks: Specific off-target activity against Claudin-9 was observed with the dual VHH binder compared to cilta-cel, indicating a potential increase in off-tumor toxicities, thereby highlighting the safety advantages of the D-Domain binder.
- Cell Activation and Cytokine Release: CAR T cell activation and cytokine release were observed with dual VHH and scFv binders in the absence of BCMA antigen, while the D-Domain did not exhibit tonic signaling, further validating its safety and specificity.
- Conference Presentation Details: The findings will be presented on February 5, 2026, at the Tandem Meetings in Salt Lake City, showcasing the D-Domain binder's potential for anti-tumor activity while minimizing tonic signaling and off-target reactivity risks.
See More
Director David Lubner Sells 6,000 Shares of Arcellx Stock
- Transaction Overview: On January 20, 2026, Director David Charles Lubner executed the sale of 6,000 shares of Arcellx common stock for approximately $450,000, indicating a significant reduction in his ownership stake.
- Ownership Stake Reduction: This transaction reduced Lubner's direct holdings by 21.69%, from 27,659 shares to 21,659 shares, while his 59,405 options remained unchanged, suggesting a potential shift in confidence regarding the company's future.
- Market Performance Insight: As of January 20, 2026, Arcellx's stock price stood at $68.31 with a market capitalization of $3.95 billion; despite a 15% decline in stock value in 2025, the company has sufficient funding to operate through 2028, indicating some financial stability.
- Clinical Development and Investor Outlook: Arcellx has made significant progress with its multiple myeloma treatment, advancing to phase two development, which could become a major revenue driver if successful, although the company still faces challenges with negative operating income.
See More
FDA Draft Guidance Boosts Arcellx (ACLX) and Legend Biotech (LEGN) Stock Prices
- FDA Guidance Impact: The U.S. FDA's draft guidance allows minimal residual disease and complete response as endpoints for accelerated approval in multiple myeloma treatments, leading to a stock price increase for Arcellx (ACLX) and Legend Biotech (LEGN), reflecting market optimism for new therapies.
- Collaborative Prospects: Legend Biotech's partnership with Johnson & Johnson (JNJ) on the Carvykti cell therapy has already incorporated MRD negativity as an endpoint in the CARTITUDE-6 trial, which analysts view as a positive development for its market performance.
- Market Competition Analysis: Analysts highlight that Arcellx's anito-cel therapy is also expected to enter the market based on MRD negativity, enhancing its competitiveness in the second to fourth-line treatment settings and increasing investment appeal in this sector.
- Investment Rating Changes: Jefferies maintains an Outperform rating on Legend Biotech with a target price of $66, noting that while the stock trades at a significant discount, the FDA guidance provides a clear positive signal for its future growth.
See More
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
See More
